The Lusvertikimab Biosimilar IL7RA Antibody is a cutting-edge biologic designed for research involving IL7RA, a cell surface receptor implicated in immune regulation and response. This innovative antibody, produced using state-of-the-art biotechnology, is highly specific and reactive with human samples, making it an ideal tool for studies in immunology and oncology.IL7RA, also known as interleukin-7 receptor alpha, plays a critical role in immune cell development and function by modulating lymphocyte survival and proliferation. Targeting IL7RA has shown promise in the development of novel immunotherapies for diseases such as cancer and autoimmune disorders.
This biosimilar antibody binds to IL7RA with high affinity, enabling precise detection and analysis in various cell types and tissues.Understanding the role of IL7RA in immune responses is essential for advancing research and developing targeted therapies that harness the immune system to combat diseases. The Lusvertikimab Biosimilar Anti-IL7RA Antibody offers researchers a powerful tool to explore the functions of IL7RA and uncover new insights into immune regulation and disease pathogenesis.
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Storage & Shipping:
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing).Lyophilized antibodies are shipped at ambient temperature.
Common Name:
Effi-7,Effi7-h,MD-707
Buffer:
Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions.
Format:
Powder
Applications
Flow Cyt
Antibody Isotype:
IgG4
Guarantee:
12 months from date of dispatch
Background:
Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
